Stay updated on Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The ClinicalTrials.gov record for the ocrelizumab multiple sclerosis study is available, with its study design, participant criteria, sites, outcome measures, and record dates. The record indicates the study is completed and is no longer recruiting participants.
    Difference
    57%
    Check dated 2026-11-08T23:17:50.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The displayed site revision changed from v3.7.2 to v3.8.0. The study record remains behind a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T23:18:14.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    A site-wide banner announces an NIH terminology transition, noting that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.
    Difference
    1%
    Check dated 2026-10-25T22:42:14.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision identifier advanced from v3.7.1 to v3.7.2 on the page displaying a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:55:11.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T23:08:29.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error, replacing the previous study details and navigation; users will see an error page instead of the trial information.
    Difference
    18%
    Check dated 2026-09-20T20:50:10.000Z thumbnail image

Stay in the know with updates to Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Ocrelizumab in Multiple Sclerosis Clinical Trial page.